Mitoxantrone in the treatment of advanced uterine sarcoma : a phase II trial of the gynecologic oncology group
Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks. All patients had good performance status and measurable disease. Nineteen had prior chemotherapy but only five had prio...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical oncology 1990-02, Vol.13 (1), p.32-34 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 1 |
| container_start_page | 32 |
| container_title | American journal of clinical oncology |
| container_volume | 13 |
| creator | MUSS, H. B BUNDY, B. N ADCOCK, L BEECHAM, J |
| description | Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks. All patients had good performance status and measurable disease. Nineteen had prior chemotherapy but only five had prior doxorubicin. No complete or partial responses were seen in 12 patients with leiomyosarcoma (95% confidence interval for a response of 0-22%) or 17 patients with mixed mesodermal tumors (95% confidence interval for a response of 0-16%). The median progression-free interval for patients with leiomyosarcoma was 1.4 months and the median survival 4.1 months. The median progression-free interval for patients with mixed mesodermal was 1.4 months and median survival 4.0 months. Mitoxantrone does not appear to be very active against leiomyosarcoma or mixed mesodermal tumors as second-line therapy. |
| doi_str_mv | 10.1097/00000421-199002000-00009 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79637183</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79637183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c285t-fc68e7fd3359d7f63caec263f4dc84c35f5680eadc57f99ba91dda6c232ce2003</originalsourceid><addsrcrecordid>eNpFkE1v1DAQhi0EareFn4DkC9xS_BHHcW-oArpSEReQuEVTe7xNldhb26nYf4_TLsUXe2aedyw9hFDOLjgz-hNbTyt4w41hTNSiWTvmFdlwJXXTKvn7NdkwoXUjtRSn5Czn-0qojukTciK4ao3gGxK-jyX-gVBSDEjHQMsd0pIQyoyh0OgpuEcIFh1dCqaxQhmSjTPQSwp0fwcZ6XZbIyNMK77md4eANk5xN1oaw9PrQHcpLvu35I2HKeO7431Ofn398vPqurn58W179fmmsaJXpfG261F7J6UyTvtOWkArOulbZ_vWSuVV1zMEZ5X2xtyC4c5BZ4UUFqsNeU4-Pu_dp_iwYC7DPGaL0wQB45IHbTqpeS8r2D-DNsWcE_phn8YZ0mHgbFhVD_9UDy-qn1qmRt8f_1huZ3QvwaPbOv9wnEO2MPlUNY75_34jhe6ZkH8BGmCH9g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79637183</pqid></control><display><type>article</type><title>Mitoxantrone in the treatment of advanced uterine sarcoma : a phase II trial of the gynecologic oncology group</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>MUSS, H. B ; BUNDY, B. N ; ADCOCK, L ; BEECHAM, J</creator><creatorcontrib>MUSS, H. B ; BUNDY, B. N ; ADCOCK, L ; BEECHAM, J</creatorcontrib><description>Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks. All patients had good performance status and measurable disease. Nineteen had prior chemotherapy but only five had prior doxorubicin. No complete or partial responses were seen in 12 patients with leiomyosarcoma (95% confidence interval for a response of 0-22%) or 17 patients with mixed mesodermal tumors (95% confidence interval for a response of 0-16%). The median progression-free interval for patients with leiomyosarcoma was 1.4 months and the median survival 4.1 months. The median progression-free interval for patients with mixed mesodermal was 1.4 months and median survival 4.0 months. Mitoxantrone does not appear to be very active against leiomyosarcoma or mixed mesodermal tumors as second-line therapy.</description><identifier>ISSN: 0277-3732</identifier><identifier>EISSN: 1537-453X</identifier><identifier>DOI: 10.1097/00000421-199002000-00009</identifier><identifier>PMID: 2154921</identifier><identifier>CODEN: AJCODI</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Drug Evaluation ; Female ; Humans ; Leiomyosarcoma - drug therapy ; Medical sciences ; Middle Aged ; Mitoxantrone - therapeutic use ; Multicenter Studies as Topic ; Neoplasm Recurrence, Local - drug therapy ; Neoplasms, Germ Cell and Embryonal - drug therapy ; Pharmacology. Drug treatments ; Remission Induction ; Survival Rate ; Uterine Neoplasms - drug therapy</subject><ispartof>American journal of clinical oncology, 1990-02, Vol.13 (1), p.32-34</ispartof><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19327802$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2154921$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MUSS, H. B</creatorcontrib><creatorcontrib>BUNDY, B. N</creatorcontrib><creatorcontrib>ADCOCK, L</creatorcontrib><creatorcontrib>BEECHAM, J</creatorcontrib><title>Mitoxantrone in the treatment of advanced uterine sarcoma : a phase II trial of the gynecologic oncology group</title><title>American journal of clinical oncology</title><addtitle>Am J Clin Oncol</addtitle><description>Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks. All patients had good performance status and measurable disease. Nineteen had prior chemotherapy but only five had prior doxorubicin. No complete or partial responses were seen in 12 patients with leiomyosarcoma (95% confidence interval for a response of 0-22%) or 17 patients with mixed mesodermal tumors (95% confidence interval for a response of 0-16%). The median progression-free interval for patients with leiomyosarcoma was 1.4 months and the median survival 4.1 months. The median progression-free interval for patients with mixed mesodermal was 1.4 months and median survival 4.0 months. Mitoxantrone does not appear to be very active against leiomyosarcoma or mixed mesodermal tumors as second-line therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Drug Evaluation</subject><subject>Female</subject><subject>Humans</subject><subject>Leiomyosarcoma - drug therapy</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mitoxantrone - therapeutic use</subject><subject>Multicenter Studies as Topic</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasms, Germ Cell and Embryonal - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Remission Induction</subject><subject>Survival Rate</subject><subject>Uterine Neoplasms - drug therapy</subject><issn>0277-3732</issn><issn>1537-453X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1v1DAQhi0EareFn4DkC9xS_BHHcW-oArpSEReQuEVTe7xNldhb26nYf4_TLsUXe2aedyw9hFDOLjgz-hNbTyt4w41hTNSiWTvmFdlwJXXTKvn7NdkwoXUjtRSn5Czn-0qojukTciK4ao3gGxK-jyX-gVBSDEjHQMsd0pIQyoyh0OgpuEcIFh1dCqaxQhmSjTPQSwp0fwcZ6XZbIyNMK77md4eANk5xN1oaw9PrQHcpLvu35I2HKeO7431Ofn398vPqurn58W179fmmsaJXpfG261F7J6UyTvtOWkArOulbZ_vWSuVV1zMEZ5X2xtyC4c5BZ4UUFqsNeU4-Pu_dp_iwYC7DPGaL0wQB45IHbTqpeS8r2D-DNsWcE_phn8YZ0mHgbFhVD_9UDy-qn1qmRt8f_1huZ3QvwaPbOv9wnEO2MPlUNY75_34jhe6ZkH8BGmCH9g</recordid><startdate>19900201</startdate><enddate>19900201</enddate><creator>MUSS, H. B</creator><creator>BUNDY, B. N</creator><creator>ADCOCK, L</creator><creator>BEECHAM, J</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900201</creationdate><title>Mitoxantrone in the treatment of advanced uterine sarcoma : a phase II trial of the gynecologic oncology group</title><author>MUSS, H. B ; BUNDY, B. N ; ADCOCK, L ; BEECHAM, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c285t-fc68e7fd3359d7f63caec263f4dc84c35f5680eadc57f99ba91dda6c232ce2003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Drug Evaluation</topic><topic>Female</topic><topic>Humans</topic><topic>Leiomyosarcoma - drug therapy</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mitoxantrone - therapeutic use</topic><topic>Multicenter Studies as Topic</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasms, Germ Cell and Embryonal - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Remission Induction</topic><topic>Survival Rate</topic><topic>Uterine Neoplasms - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MUSS, H. B</creatorcontrib><creatorcontrib>BUNDY, B. N</creatorcontrib><creatorcontrib>ADCOCK, L</creatorcontrib><creatorcontrib>BEECHAM, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MUSS, H. B</au><au>BUNDY, B. N</au><au>ADCOCK, L</au><au>BEECHAM, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitoxantrone in the treatment of advanced uterine sarcoma : a phase II trial of the gynecologic oncology group</atitle><jtitle>American journal of clinical oncology</jtitle><addtitle>Am J Clin Oncol</addtitle><date>1990-02-01</date><risdate>1990</risdate><volume>13</volume><issue>1</issue><spage>32</spage><epage>34</epage><pages>32-34</pages><issn>0277-3732</issn><eissn>1537-453X</eissn><coden>AJCODI</coden><abstract>Twenty-nine evaluable patients with metastatic or recurrent leiomyosarcoma or malignant mixed mesodermal tumors of the uterus were treated with mitoxantrone 12 mg/m2 every 3 weeks. All patients had good performance status and measurable disease. Nineteen had prior chemotherapy but only five had prior doxorubicin. No complete or partial responses were seen in 12 patients with leiomyosarcoma (95% confidence interval for a response of 0-22%) or 17 patients with mixed mesodermal tumors (95% confidence interval for a response of 0-16%). The median progression-free interval for patients with leiomyosarcoma was 1.4 months and the median survival 4.1 months. The median progression-free interval for patients with mixed mesodermal was 1.4 months and median survival 4.0 months. Mitoxantrone does not appear to be very active against leiomyosarcoma or mixed mesodermal tumors as second-line therapy.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>2154921</pmid><doi>10.1097/00000421-199002000-00009</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0277-3732 |
| ispartof | American journal of clinical oncology, 1990-02, Vol.13 (1), p.32-34 |
| issn | 0277-3732 1537-453X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_79637183 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Antineoplastic agents Biological and medical sciences Chemotherapy Drug Evaluation Female Humans Leiomyosarcoma - drug therapy Medical sciences Middle Aged Mitoxantrone - therapeutic use Multicenter Studies as Topic Neoplasm Recurrence, Local - drug therapy Neoplasms, Germ Cell and Embryonal - drug therapy Pharmacology. Drug treatments Remission Induction Survival Rate Uterine Neoplasms - drug therapy |
| title | Mitoxantrone in the treatment of advanced uterine sarcoma : a phase II trial of the gynecologic oncology group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T15%3A51%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitoxantrone%20in%20the%20treatment%20of%20advanced%20uterine%20sarcoma%20:%20a%20phase%20II%20trial%20of%20the%20gynecologic%20oncology%20group&rft.jtitle=American%20journal%20of%20clinical%20oncology&rft.au=MUSS,%20H.%20B&rft.date=1990-02-01&rft.volume=13&rft.issue=1&rft.spage=32&rft.epage=34&rft.pages=32-34&rft.issn=0277-3732&rft.eissn=1537-453X&rft.coden=AJCODI&rft_id=info:doi/10.1097/00000421-199002000-00009&rft_dat=%3Cproquest_cross%3E79637183%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79637183&rft_id=info:pmid/2154921&rfr_iscdi=true |